http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2308271-C1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1a771cb782949935ecf50376678f7770
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a8a776e18b1120f660a4ecd23a67f52b
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4985
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
filingDate 2006-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2007-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a4c84bf418970f015a6ed0eb14904e03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b684b88c53890b52523436b60b7bb44
publicationDate 2007-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber RU-2308271-C1
titleOfInvention Method for preventing the development of erectile dysfunction in patients after urethral trauma
abstract FIELD: medicine, urology, sexopathology. n SUBSTANCE: about 4-5 wk after the trauma it is necessary to introduce Impaza for a patient per 1 tablet before meals in the morning during 1-2 month every other day. Then during 5-6 month additionally during the days between Impaza intake it is necessary to introduce Levitra at the dosage of 5 mg after meals in the morning twice or thrice weekly. Then Levitra intake should be stopped to continue Impaza intake for 1-2 mo more. Due to the scheme of stage-by-stage introduction of medicinal preparations the innovation prevent the hemorrhage out of traumatic areas and, also, the development of ischemia and fibrosis of cavernous bodies at early stages after urethral trauma. n EFFECT: higher efficiency of therapy. n 6 dwg, 2 ex
priorityDate 2006-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419587674
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID522325
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID152743216
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419590105
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCO61309
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID178137
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID6574
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ8T8C0
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID692510
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415818389
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID117909
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419525056
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ9I9M2
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419590271
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135400189
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419532884
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5280723
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCO61608
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID178137
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID4328006
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ27571
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID149096
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419506374
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135398744
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135398631
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID453878741
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5744
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419506981
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID6574
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID408264951
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23665888
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID34495

Total number of triples: 47.